ES2119250T3 - Composiciones y metodos para estimular el crecimiento y diferenciacion de megacariocitos. - Google Patents

Composiciones y metodos para estimular el crecimiento y diferenciacion de megacariocitos.

Info

Publication number
ES2119250T3
ES2119250T3 ES95104745T ES95104745T ES2119250T3 ES 2119250 T3 ES2119250 T3 ES 2119250T3 ES 95104745 T ES95104745 T ES 95104745T ES 95104745 T ES95104745 T ES 95104745T ES 2119250 T3 ES2119250 T3 ES 2119250T3
Authority
ES
Spain
Prior art keywords
growth
presented
megacariocitos
stimulate
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95104745T
Other languages
English (en)
Inventor
Timothy D Bartley
Jakob M Bogenberger
Robert A Bosselman
Pamela Hunt
Babru B Samal
Olaf B Kinstler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/321,488 external-priority patent/US5795569A/en
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ES2119250T3 publication Critical patent/ES2119250T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE PRESENTAN NUEVAS PROTEINAS, REFERENCIAS COMO FACTORES PARA EL CRECIMIENTO Y DESARROLLO DE LOS MEGACARIOCITOS (MGDFS; TAMBIEN GENERALMENTE REFERIDAS COMO LIGANTES MPL), QUE TIENEN ACTIVIDAD BIOLOGICA PARA ESTIMULAR EL CRECIMIENTO DE LOS MEGACARIOCITOS Y AUMENTAR LA DIFERENCIACION O MADURACION DE LOS MEGACARIOCITOS, ULTIMAMENTE PARA DAR COMO RESULTADO LA PRODUCCION DE PLAQUETAS. LOS DERIVADOS DEL MGDF QUE COMPRENDEN MOLECULAS DE MGDF SUJETAS A POLIMEROS SOLUBLES EN AGUA, TALES COMO GLICOL DE POLIETILENO, SON TAMBIEN PRESENTADOS, JUNTO CON METODOS PARA SU PREPARACION. TAMBIEN SE PRESENTAN PROCESOS PARA OBTENER LOS MGDFS EN FORMA HOMOGENEA A PARTIR DE FUENTES NATURALES Y PARA PRODUCIRLOS POR TECNICAS DE INGENIERIA GENETICA RECOMBINANTE A PARTIR DE MAMIFEROS, INCLUYENDO LOS HUMANOS.
ES95104745T 1994-03-31 1995-03-30 Composiciones y metodos para estimular el crecimiento y diferenciacion de megacariocitos. Expired - Lifetime ES2119250T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22176894A 1994-03-31 1994-03-31
US25262894A 1994-05-31 1994-05-31
US08/321,488 US5795569A (en) 1994-03-31 1994-10-12 Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
US34778094A 1994-11-30 1994-11-30

Publications (1)

Publication Number Publication Date
ES2119250T3 true ES2119250T3 (es) 1998-10-01

Family

ID=27499246

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95104745T Expired - Lifetime ES2119250T3 (es) 1994-03-31 1995-03-30 Composiciones y metodos para estimular el crecimiento y diferenciacion de megacariocitos.

Country Status (32)

Country Link
US (1) US5766581A (es)
EP (3) EP0755263A4 (es)
JP (2) JP2996415B2 (es)
KR (2) KR100303810B1 (es)
CN (2) CN1103782C (es)
AT (1) ATE169335T1 (es)
AU (1) AU691606B2 (es)
BG (1) BG62685B1 (es)
BR (1) BR9506017A (es)
CA (1) CA2167090C (es)
CZ (2) CZ288926B6 (es)
DE (1) DE69503849T2 (es)
DK (1) DK0690127T3 (es)
EE (1) EE9600121A (es)
ES (1) ES2119250T3 (es)
FI (1) FI960136A (es)
GE (1) GEP20002180B (es)
GR (1) GR3027593T3 (es)
HK (2) HK1004231A1 (es)
HU (1) HU218893B (es)
IL (1) IL113206A0 (es)
LV (2) LV11783B (es)
MY (1) MY113048A (es)
NO (1) NO960111L (es)
NZ (1) NZ283863A (es)
PL (1) PL182567B1 (es)
RO (1) RO115788B1 (es)
SI (1) SI0690127T1 (es)
SK (1) SK166695A3 (es)
TW (3) TW414799B (es)
WO (1) WO1995026746A1 (es)
YU (1) YU20095A (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1996017062A1 (en) * 1994-11-30 1996-06-06 Zymogenetics, Inc. Low molecular weight thrombopoietin
US5986049A (en) * 1994-12-30 1999-11-16 Zymogenetics, Inc. Purified thrombopoietin and method of making it
TW387940B (en) * 1995-01-17 2000-04-21 Kirin Brewery Anti-tpo monodonal antibody
JPH11500308A (ja) 1995-02-03 1999-01-12 ジー．ディー．サール アンド カンパニー 新規ｃ−ＭＰＬリガンド
MX9705943A (es) * 1995-02-15 1997-10-31 Amgen Inc Analogos de ligando mpl.
US5989538A (en) * 1995-02-15 1999-11-23 Amgen Inc. Mpl ligand analogs
US5696250A (en) * 1995-02-15 1997-12-09 Amgen Inc. DNA encoding megakaryocyte growth and development factor analogs
TW434021B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable TPO-containing compositions
TW434020B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable top-containing compositions
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6251864B1 (en) 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
ZA964814B (en) 1995-06-07 1998-02-09 Glaxo Group Ltd Peptides and compounds that bind to a receptor.
TW497972B (en) * 1995-06-08 2002-08-11 Kirin Brewery Stable thrombopoietin (TPO)-containing lyophilized compositions
US6066318A (en) * 1995-10-05 2000-05-23 G.D. Searle & Co. Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
JP2000513924A (ja) * 1995-10-05 2000-10-24 ジー．ディー．サール アンド カンパニー 新規ｃ−ｍｐｌ受容体アゴニスト
US5879673A (en) * 1996-01-25 1999-03-09 Genentech, Inc. Administration of thrombopoietin on a single day only
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
KR100408229B1 (ko) * 1996-10-04 2003-12-01 암겐 인코포레이티드 Ｍｐｌ 리간드를 함유하는 제약학적 조성물
US5914251A (en) 1996-10-22 1999-06-22 Amgen Inc. Nucleic acid molecules encoding placental-derived growth factors
AU7589898A (en) * 1997-05-21 1998-12-11 Genentech Inc. Novel administration of thrombopoietin
AU2006201129B2 (en) * 1997-05-21 2008-03-13 Genentech, Inc. Novel administration of thrombopoietin
JP4574007B2 (ja) 1998-04-28 2010-11-04 メルク・セローノ・ソシエテ・アノニム ポリオール−ｉｆｎ−ベータ複体
US20030228666A1 (en) 1998-06-30 2003-12-11 Daewoong Pharmaceutical Co., Ltd. Novel human thrombopoietin mutein
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
TWI257394B (en) 1998-10-23 2006-07-01 Kirin Amgen Inc Thrombopoietic compounds
US6589759B1 (en) 1999-03-30 2003-07-08 Trustees Of Boston University Compositions and methods for producing platelets and/or proplatelets from megakaryocytes
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
JP4799801B2 (ja) 2000-08-11 2011-10-26 協和発酵キリン株式会社 リン酸代謝、カルシウム代謝、石灰化及びビタミンｄ代謝を調節するポリペプチド並びにそれをコードするｄｎａ
WO2002015926A1 (fr) * 2000-08-24 2002-02-28 Kirin Beer Kabushiki Kaisha Compositions medicinales contenant des ligands c-mpl, destinees a l'augmentation des plaquettes et des erythrocytes
UY26317A1 (es) * 2000-08-30 2000-10-31 Alfonso Cayota Carlos Pritsch Sistema de produccion de trombopoyetina humana por celulas de mamiferos en cultivo
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US20040028661A1 (en) * 2002-08-07 2004-02-12 Bartelmez Stephen H. Expansion of cells using thrombopoietin and anti-transforming growth factor-beta
WO2004014938A2 (en) * 2002-08-09 2004-02-19 Xencor Thrombopoiesis-stimulating proteins having reduced immunogenicity
MXPA05003057A (es) 2002-09-18 2006-04-18 Johnson & Johnson Metodos para aumentar la produccion de celulas madre hematopoyeticas y plaquetas.
RS20050501A (en) * 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polymer conjugates of cytokines,chemokines,growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
RS20050502A (en) * 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polymer conjugates of interferon- beta with enhanced biological potency
EP1594508B1 (en) * 2003-02-11 2012-08-08 Irm Llc Novel bicyclic compounds and compositions
US7871607B2 (en) * 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US20090123367A1 (en) * 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
JP4464395B2 (ja) * 2003-03-05 2010-05-19 ヘイローザイム インコーポレイテッド 可溶性ヒアルロニダーゼ糖タンパク質（ｓＨＡＳＥＧＰ）、その調製プロセス、使用およびそれを含む薬学的組成物
US7642340B2 (en) 2003-03-31 2010-01-05 Xencor, Inc. PEGylated TNF-α variant proteins
EP1610825A2 (en) * 2003-03-31 2006-01-04 Xencor, Inc. Methods for rational pegylation of proteins
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
US7723295B2 (en) 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
CN102241742B (zh) 2003-08-28 2014-04-02 奥索-麦克尼尔药品公司 结合血小板生成素受体的肽和化合物
AU2004279895A1 (en) 2003-10-10 2005-04-21 Xencor, Inc Protein based TNF-alpha variants for the treatment of TNF-alpha related disorders
BRPI0418326A (pt) 2003-12-30 2007-05-02 Bionethos Holding Gmbh método de regeneração de tecidos
WO2005118551A2 (en) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
WO2005123113A2 (en) * 2004-06-14 2005-12-29 Intermune, Inc. Interferon compositions and methods of use thereof
WO2006010057A2 (en) 2004-07-08 2006-01-26 Amgen Inc. Therapeutic peptides
EP1768700B1 (en) * 2004-07-16 2010-12-15 Nektar Therapeutics Conjugates comprising gm-csf and a polymer
AU2005299720B2 (en) * 2004-10-25 2010-02-04 Ligand Pharmaceuticals Incorporated Thrombopoietin activity modulating compounds and methods
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2007102946A2 (en) 2006-01-23 2007-09-13 Amgen Inc. Crystalline polypeptides
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
US8318153B2 (en) * 2006-06-29 2012-11-27 Nalin David R Method of medically treating an individual
EP2162540A2 (en) 2007-05-22 2010-03-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
EP2285402A2 (en) 2008-04-14 2011-02-23 Halozyme, Inc. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
DK3037529T3 (da) 2008-12-09 2019-05-20 Halozyme Inc Udvidede opløselige ph20-polypeptider og anvendelse deraf
JP5770635B2 (ja) 2008-12-16 2015-08-26 ダウ コーニング コーポレーションＤｏｗ Ｃｏｒｎｉｎｇ Ｃｏｒｐｏｒａｔｉｏｎ シロキサンの製造方法
KR101040396B1 (ko) 2009-01-20 2011-06-09 한올바이오파마주식회사 변형된 인간 트롬보포이에틴 폴리펩타이드 절편 및 그의 제조방법
US8680150B2 (en) * 2009-05-28 2014-03-25 Ligand Pharmaceuticals, Inc. Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors
JP2012528184A (ja) 2009-05-29 2012-11-12 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー トロンボポエチンアゴニスト化合物の投与の方法
JP5734985B2 (ja) 2009-09-17 2015-06-17 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ ヒアルロニダーゼおよび免疫グロブリンの安定な共製剤およびそれらの使用方法
WO2011098095A1 (en) 2010-02-09 2011-08-18 Aplagen Gmbh Peptides binding the tpo receptor
US9878046B2 (en) 2010-07-20 2018-01-30 Halozyme, Inc. Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects
WO2012109387A1 (en) 2011-02-08 2012-08-16 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
CN103889443A (zh) 2011-06-17 2014-06-25 哈洛齐梅公司 使用透明质酸降解酶的持续皮下胰岛素输注法
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
US20130071394A1 (en) 2011-09-16 2013-03-21 John K. Troyer Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
AU2012328880B2 (en) 2011-10-24 2017-02-23 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
IL298330A (en) 2011-12-30 2023-01-01 Halozyme Inc Ph20 polypeptide variants, formulations and uses thereof
EA031986B1 (ru) 2012-04-04 2019-03-29 Галозим, Инк. Способ и комбинация для лечения солидной раковой опухоли и набор, содержащий комбинацию
US9278124B2 (en) 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
HUE043847T2 (hu) 2014-08-28 2019-09-30 Halozyme Inc Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia
EA201700181A1 (ru) 2014-10-14 2017-09-29 Галозим, Инк. Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
US10781435B2 (en) 2017-06-22 2020-09-22 Catalyst Biosciences, Inc. Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
EP3902913A1 (en) 2018-12-28 2021-11-03 Catalyst Biosciences, Inc. Modified urokinase-type plasminogen activator polypeptides and methods of use

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
EP0154316B1 (en) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
DE3675588D1 (de) * 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4894440A (en) * 1986-09-17 1990-01-16 Massachusetts Institute Of Technology Method of isolating megakaryocyte stimulatory factor
ZA887773B (en) * 1987-10-26 1989-07-26 Immunex Corp Interleukin-7
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
CA1340810C (en) * 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
IL90719A0 (en) * 1988-06-28 1990-01-18 Yissum Res Dev Co Novel nuclei acids and polypeptides encoded thereby
US5128449A (en) * 1988-07-05 1992-07-07 The University Of Tennessee Research Corporation Polypeptide and a method for its production
DE68928138T2 (de) * 1988-09-21 1997-10-02 Meiji Seika Kaisha Neuer megakaryokytischer koloniestimulierender faktor und verfahren zur herstellung
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
ATE135370T1 (de) * 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5087448A (en) * 1989-02-02 1992-02-11 The Board Of Regents Of The University Of Oklahoma Enhancing growth of megakaryocytes in mammals using interleuking 6
US5032396A (en) * 1989-02-17 1991-07-16 Immunex Corporation IL-7 to stimulate platelet production
JPH04506513A (ja) * 1989-04-03 1992-11-12 ジェネティックス・インスティテュート・インコーポレイテッド 巨核球増殖促進活性
US5260417A (en) * 1989-04-03 1993-11-09 Genetics Institute, Inc. Megakaryocyte growth promoting activity protein
AU5355790A (en) * 1989-04-19 1990-11-16 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
US6433142B1 (en) * 1989-08-08 2002-08-13 Genetics Institute, Llc Megakaryocyte stimulating factors
DK15492A (da) * 1989-08-08 1992-02-07 Genentech Inst Inc En megakaryocytopoietisk faktor
US5215895A (en) * 1989-11-22 1993-06-01 Genetics Institute, Inc. Dna encoding a mammalian cytokine, interleukin-11
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
CA2084074A1 (en) * 1990-05-31 1991-12-01 Keita Matsunaga Megakaryocyte colony stimulating factor and production thereof
EP0540575A4 (en) * 1990-07-02 1994-06-08 Hipple Cancer Res Center Human meg-csf protein and methods
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
WO1992006178A1 (en) * 1990-10-05 1992-04-16 Systemix, Inc. Megakaryocyte and platelet growth, production and composition
AU8868891A (en) * 1990-10-12 1992-05-20 Amgen, Inc. Megakaryocyte maturation factors
WO1992007074A1 (fr) * 1990-10-19 1992-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptide de la famille d'un recepteur de facteur de croissance, application au diagnostic et a la therapie des maladies myeloproliferatives
WO1992012177A1 (fr) * 1990-12-28 1992-07-23 Asahi Kasei Kogyo Kabushiki Kaisha Nouvel amplificateur de megakaryocyte et sa production
JP3283288B2 (ja) * 1991-03-08 2002-05-20 電気化学工業株式会社 生理活性ペプチド製剤
JPH04295500A (ja) * 1991-03-26 1992-10-20 Asahi Chem Ind Co Ltd 新規な巨核球増幅因子とその製法
CA2112492A1 (en) * 1991-06-28 1993-01-07 Hava Avraham A differentiated megakaryocyte line producing novel megakaryocyte differentiation factors
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
US5250732A (en) * 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
NZ244778A (en) * 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
JP3328341B2 (ja) * 1991-12-27 2002-09-24 中外製薬株式会社 新規な巨核球増幅因子
AU3463493A (en) * 1992-02-07 1993-09-03 Asahi Kasei Kogyo Kabushiki Kaisha Novel megakaryocyte amplifier and production thereof
AU4190893A (en) * 1992-07-17 1994-01-20 Suntory Limited Megakaryocyte differentiation factor
GB2285446B (en) * 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
EP0668352A1 (en) * 1994-02-14 1995-08-23 Kirin Brewery Company, Ltd. Protein having TPO activity
WO1995021919A2 (en) * 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
CZ221496A3 (en) * 1994-02-14 1997-07-16 Zymogenetics Inc Haematopoetic protein, materials and processes for preparing thereof
WO1995021626A1 (en) * 1994-02-14 1995-08-17 University Of Washington Methods for stimulating erythropoiesis using thrombopoietin
US5547931A (en) * 1994-02-23 1996-08-20 Immtech International Inc. Methods of stimulatory thrombocytopoiesis using modified C-reactive protein
US5571686A (en) * 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets

Also Published As

Publication number Publication date
YU20095A (sh) 1998-08-14
CA2167090A1 (en) 1995-10-12
KR100303810B1 (ko) 2001-12-01
RO115788B1 (ro) 2000-06-30
CZ350595A3 (en) 1997-01-15
LV11783A (lv) 1997-06-20
FI960136A (fi) 1996-03-11
JP2000103799A (ja) 2000-04-11
CN1322759A (zh) 2001-11-21
WO1995026746A1 (en) 1995-10-12
EE9600121A (et) 1997-04-15
KR100203824B1 (ko) 1999-06-15
CN1103782C (zh) 2003-03-26
ATE169335T1 (de) 1998-08-15
DE69503849D1 (de) 1998-09-10
MX9600206A (es) 1998-11-30
DK0690127T3 (da) 1999-05-03
TW565568B (en) 2003-12-11
NO960111L (no) 1996-09-24
CZ288890B6 (cs) 2001-09-12
PL182567B1 (pl) 2002-01-31
JPH10510980A (ja) 1998-10-27
GR3027593T3 (en) 1998-11-30
CN1229385C (zh) 2005-11-30
EP0755263A1 (en) 1997-01-29
BG100625A (bg) 1997-04-30
HU218893B (hu) 2000-12-28
SI0690127T1 (en) 1998-12-31
AU2230895A (en) 1995-10-23
CN1137757A (zh) 1996-12-11
HK1004231A1 (en) 1998-11-20
NZ283863A (en) 1997-12-19
EP0690127B1 (en) 1998-08-05
JP3485842B2 (ja) 2004-01-13
JP2996415B2 (ja) 1999-12-27
HUT74257A (en) 1996-11-28
EP0675201A1 (en) 1995-10-04
PL312577A1 (en) 1996-04-29
LV12275B (en) 1999-08-20
TW496870B (en) 2002-08-01
EP0690127A1 (en) 1996-01-03
HU9600059D0 (en) 1996-03-28
US5766581A (en) 1998-06-16
MY113048A (en) 2001-11-30
TW414799B (en) 2000-12-11
LV11783B (en) 1997-12-20
SK166695A3 (en) 1997-02-05
NO960111D0 (no) 1996-01-10
HK1041275B (zh) 2006-07-28
FI960136A0 (fi) 1996-01-11
CZ288926B6 (cs) 2001-09-12
CA2167090C (en) 2002-05-14
BR9506017A (pt) 1997-10-14
BG62685B1 (bg) 2000-05-31
LV12275A (lv) 1999-05-20
HK1041275A1 (en) 2002-07-05
AU691606B2 (en) 1998-05-21
GEP20002180B (en) 2000-07-25
DE69503849T2 (de) 1999-04-01
IL113206A0 (en) 1995-06-29
EP0755263A4 (en) 2005-02-09

Similar Documents

Publication Publication Date Title
ES2119250T3 (es) Composiciones y metodos para estimular el crecimiento y diferenciacion de megacariocitos.
ATE142691T1 (de) Proteine mit faktor-viii-aktivität, verfahren zu deren herstellung unter verwendung von genetisch modifizierten zellen und diese enthaltende pharmazeutische zusammensetzungen
AR020735A1 (es) Un procedimiento para la obtencion de un polipeptido glucosilado a partir de celulas eucarioticas
DE69433013D1 (de) Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
DE3781204T2 (de) Verfahren zur herstellung von lymphokinaktivierten toetenden zellen.
DK0559884T3 (da) Rekombinante virusvektorer til ekspression i muskelceller
ATE270323T1 (de) Zusammensetzungen und verfahren zur stimulierung der proliferation und der differenzierung von menschlichen fetalen und erwachsenen pankreatischen zellen ex vivo
ES2147720T3 (es) Factor de celulas madre.
ATE71144T1 (de) Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung.
MX9206456A (es) Nuevos hibridos transformadores de los factores de crecimiento.
CN106190946A (zh) 一种用于干细胞扩增的培养基
BR9811014A (pt) "região concentrada reguladora de gene especìfica para semente precoce"
BR112021019139A2 (pt) Célula de mamífero manipulada, composição, molécula isolada de dna de fita dupla, dispositivo implantável, cápsula de hidrogel, e, método de tratamento de um paciente com doença de fabry
Lim et al. Morphological transforming factor: influence on histotypic organization of epithelial brain cells
CN101302529A (zh) 共表达gdnf和bdnf的转基因神经干细胞
CN106727246A (zh) 小牛血清细胞营养液
BR9911388A (pt) Imunógeno de somatostatina sintético para promoção de crescimento em animais de fazenda
DE69941849D1 (de) Herstellung eines biologischen faktors und schaffung einer immunologisch vorteilhaften umgebung unter verwendung genetisch veränderter sertolizellen
Abbas et al. 109. Vitamin E Treated Fat Grafts Maintain Volume to Improve Grafting Effects on Radiation-induced Fibrosis
AR068104A2 (es) Procedimiento in vitro para la produccion de muteinas de polipeptidos eucarioticos ; procedimiento in vitro para la obtencion de una celula humana que expresa una muteina de un polipeptido blanco humano. celula humana obtenible por dicho procedimiento y uso de dicha celula humana

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 690127

Country of ref document: ES